• Earlier this week, Edwards Lifesciences reported new clinical data at the New York Valves 2026 conference, including PROGRESS trial baseline results in moderate aortic stenosis and long-term SAPIEN 3 performance, alongside real-world outcomes for its mitral and tricuspid therapies such as PASCAL and SAPIEN M3.
• The breadth of evidence across aortic, mitral and tricuspid therapies offers investors fresh insight into how Edwards is building a data-rich structural heart portfolio that could influence physician practice patterns and therapy adoption.
• Next, we’ll examine how the new PROGRESS trial insights into earlier TAVR use may shape Edwards Lifesciences’ existing investment narrative.

Uncover the next big thing with 21 elite penny stocks that balance risk and reward.

Edwards Lifesciences Investment Narrative Recap

To own Edwards Lifesciences, you have to believe in long term, procedure driven growth in structural heart therapies, supported by consistent, high quality clinical evidence. The New York Valves 2026 data strengthens that evidence base, but does not materially change the near term focus on early TAVR indication approvals as a key catalyst or the ongoing pressures from tariffs and higher operating expenses as central risks.

Among recent updates, the new EARLY TAVR and PARTNER 3 durability data are most relevant here, because they sit at the heart of Edwards’ push into earlier stage aortic stenosis treatment. If regulators and guideline bodies ultimately broaden TAVR indications, these data could be important context for how investors think about Edwards’ capacity to support expanded use while still managing costs, tariffs and competitive intensity.

However, against this supportive clinical backdrop, rising tariff headwinds and elevated R&D spending could pressure margins in ways investors should be aware of as they consider...

Edwards Lifesciences' narrative projects $8.3 billion revenue and $2.2 billion earnings by 2029. This requires 9.6% yearly revenue growth and roughly a $1.1 billion earnings increase from $1.1 billion today.

Uncover how Edwards Lifesciences' forecasts yield a $96.92 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Three Simply Wall St Community fair value estimates cluster between US$91.91 and US$96.92, showing how closely some private investors view Edwards’ worth. Set against this, the key early TAVR catalyst and ongoing tariff risks highlight why you may want to compare several different viewpoints before forming your own expectations for the business.

Explore 3 other fair value estimates on Edwards Lifesciences - why the stock might be worth just $91.91!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Edwards Lifesciences research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Edwards Lifesciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Edwards Lifesciences' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.